Skip to content

Depression, bone loss, and other conditions linked to low testosterone

Vladimir Kotlov, MD avatar
Vladimir Kotlov, MD: Founder & CEO at Veedma
Oct 09, 2026 · 15 min read

Listen to this article as a podcast episode

July 09, 2026 · 23:51

Low testosterone, clinically male hypogonadism, is linked to depression, bone loss, muscle loss, and several other systemic conditions when a man has persistent symptoms plus biochemical deficiency confirmed on accurate, repeated morning testing. A low number alone is not a diagnosis, and symptoms alone are not enough either. Once deficiency is confirmed and LH and FSH are measured, the clinical question becomes which related conditions are present, and whether treatment is likely to help.

Find the cause before treating it

Choose a lab panel and get a clinical review with clear next steps.

Order your lab panel

Key takeaways

  • Male hypogonadism requires both persistent symptoms and consistently low testosterone, confirmed by repeat fasting morning testing. Free testosterone is measured by equilibrium dialysis or estimated with an accurate formula when total testosterone is near the lower limit or SHBG is altered.[1]
  • LH and FSH must be measured with testosterone. High LH plus low testosterone points to primary hypogonadism, in which the testes are failing. Low or normal LH plus low testosterone points to secondary or functional hypogonadism. The distinction shapes treatment, particularly for men who want to preserve fertility.[1] [2]
  • A 2019 meta analysis of 27 randomized trials including 1,890 men found a small but significant reduction in depressive symptoms with testosterone treatment.[3] In the Testosterone Trials, older men on testosterone reported slightly better mood.[4] Testosterone is still not a substitute for standard depression treatment.
  • Hypogonadism is associated with bone loss and osteoporosis risk. Testosterone treatment generally increases bone mineral density, more at the spine than at the hip in older men, but no fracture benefit has been shown.[5] [6]
  • TRAVERSE randomized 5,246 men with hypogonadism and preexisting or high cardiovascular risk.[7] Testosterone gel was noninferior to placebo for major adverse cardiovascular events over a mean 33 months of follow up. Atrial fibrillation, acute kidney injury, and pulmonary embolism were more common in the testosterone group.[7]
  • Pooled trial data do not show worsening of lower urinary tract symptoms or adverse prostate outcomes with testosterone therapy. Existing prostate cancer remains a reason not to start treatment.[1] [8] [9]

Depression and mood

Whether low testosterone causes depression remains unclear. Randomized trials show that testosterone treatment has a small effect on depressive symptoms in men.[3]

According to the Endocrine Society guideline, hypogonadism should be diagnosed only in men who have symptoms and signs consistent with testosterone deficiency together with unequivocally and consistently low testosterone.[1] Low mood on its own therefore does not establish the diagnosis. Fatigue, low motivation, irritability, and low mood overlap with primary depressive disorders, sleep disorders, and chronic medical illness. For the formal diagnostic framework, see What is low testosterone? The clinical definition most men and many doctors get wrong.

What the evidence shows for mood

A 2019 JAMA Psychiatry meta analysis pooled 27 randomized placebo controlled trials including 1,890 men.[3] It found that testosterone treatment was associated with a small but significant reduction in depressive symptoms compared with placebo. The effect was larger with higher doses in carefully selected samples. The authors noted that the included trials were heterogeneous and called for trials that make depression the primary end point.[3]

The Testosterone Trials, published in 2016 in the New England Journal of Medicine, enrolled 790 men aged 65 or older with low testosterone.[4] Men on testosterone gel reported slightly better mood and lower severity of depressive symptoms than men on placebo, but no improvement in vitality.[4] Testosterone is not a substitute for a full mental health assessment.

What testosterone can and cannot do for depression

The 2019 meta analysis describes antidepressants as the current first line treatment for depressive disorders.[3] It describes testosterone as a controversial alternative or add on treatment in men.[3]

Taken together, the evidence supports a narrow position. In a man with persistent symptoms, documented biochemical deficiency, and other manifestations of hypogonadism, testosterone may modestly improve depressive symptoms that are part of the hormonal syndrome. A man with major or persistent depression still needs standard psychiatric treatment, whether or not low testosterone is also present.

Bone loss and fracture risk

Bone loss occurs in men with hypogonadism. Men with late onset hypogonadism are at risk of osteoporosis and osteoporotic fractures.[5]

Osteopenia means bone density below normal, but not yet in the osteoporosis range. Osteoporosis means bone strength is low enough to meaningfully increase fracture risk.

The relationship between testosterone and bone loss is not all or nothing. According to a 2020 review in Andrology, preventing bone loss appears to require serum testosterone above about 200 ng/dL and estradiol above about 20 pg/mL.[5] Men with marked deficiency therefore need closer attention to skeletal health.

How low testosterone affects bone

Bone is a metabolically active tissue that continually remodels itself. Testosterone has an antiresorptive effect on bone, which may increase bone density at the lumbar spine.[10] Part of the damage from testosterone deficiency comes from relative estrogen deficiency. Men convert some testosterone to estradiol, which is important for male bone maintenance.[5] When androgen exposure falls substantially, bone turnover shifts in an unfavorable direction and bone loss accumulates.

A 2017 JAMA Internal Medicine report from the Testosterone Trials found that one year of testosterone treatment increased volumetric bone mineral density and estimated bone strength in older men with low testosterone.[6] The gains were larger in the spine than in the hip.[6]

What treatment can realistically achieve for bone

Studies of testosterone and bone density do not all agree. Most show that testosterone replacement increases bone mineral density and prevents further bone loss in men with hypogonadism.[5] That supports TRT as a useful adjunct in hypogonadal men who also have low bone density.

Testosterone has not been shown to reduce fractures, and no data are yet available on that endpoint. A rise in bone density should not be read as proof of fracture prevention.[5] The same review recommends a specific workup for osteoporosis in men with documented late onset hypogonadism, with consideration of bone active therapy. It also advises starting testosterone according to hypogonadism guidelines.[5] Testosterone is supplementary when true hypogonadism is present, not a replacement for standard osteoporosis management.

Muscle loss and physical function

Androgens help regulate body composition.[10] Men with deficiency may notice reduced muscle size, more fat accumulation, and lower exercise tolerance. This matters most in older men and in men already trending toward frailty.

Sarcopenia means age related loss of muscle mass and physical function.

Body composition is not the same as function

In the Testosterone Trials, testosterone gel did not significantly improve walking distance in the Physical Function Trial itself.[4] When men from all three trials were pooled, 20.5% of men on testosterone walked at least 50 meters farther in 6 minutes, compared with 12.6% on placebo. The authors still concluded that treatment had no benefit for walking distance.[4] Gaining lean mass on a scan or reducing fat mass does not automatically translate into substantial gains in strength, balance, or real world mobility.

Why exercise still determines the outcome

For older men, and for limiting age related muscle loss, the most reasonable approach combines two things. Testosterone is corrected when hypogonadism is confirmed, and the man does structured strength training. Resistance exercise provides the mechanical stimulus that muscle needs to grow and gain strength.

Testosterone alone did not meaningfully improve walking distance in older men in the Testosterone Trials.[4] It should not be counted on to restore physical performance in men who do not also train.

Urinary symptoms and prostate cancer

Pooled trial data do not show that testosterone therapy worsens lower urinary tract symptoms or harms prostate outcomes.[8] [9]

LUTS means lower urinary tract symptoms, such as urgency, frequency, nocturia, weak stream, or incomplete emptying. BPH means benign prostatic hyperplasia, which is noncancerous enlargement of the prostate.

What the data show for LUTS and BPH

A 2016 European Urology meta analysis pooled 14 randomized trials including 2,029 men with late onset hypogonadism.[8] The change in International Prostate Symptom Score was similar with testosterone and with placebo.[8] That contradicts the common advice that any testosterone exposure will worsen urination.

The main caution is severe baseline symptoms. The Endocrine Society guideline recommends against starting testosterone therapy in men with severe lower urinary tract symptoms.[1] Men with severe symptoms have also been underrepresented in trials, so the evidence in that group is thinner. That is a data gap, not proof of harm.

What the data show for prostate cancer

Pooled trial data do not support the old idea that testosterone “feeds” prostate cancer. A 2010 meta analysis in The Journal of Clinical Endocrinology and Metabolism covered 51 studies.[9] It found no significant effect of testosterone treatment on prostate outcomes, although the authors rated the evidence as low quality with short follow up.[9]

One important caveat remains. The Endocrine Society guideline recommends against starting testosterone, without further urological evaluation, in men with any of the following:[1]

  • prostate or breast cancer
  • a palpable prostate nodule or induration
  • a PSA above 4 ng/mL, or above 3 ng/mL in men at increased risk

For lab interpretation and PSA monitoring, see The complete low testosterone testing guide.

TRT cardiovascular safety

The TRAVERSE trial showed that testosterone therapy was noninferior to placebo for major adverse cardiovascular events in 5,246 men followed for a mean of 33 months.[7]

MACE means heart attack, stroke, or cardiovascular death.

The TRAVERSE trial was published in 2023 in the New England Journal of Medicine.[7] It enrolled men aged 45 to 80 who had symptoms of hypogonadism and two fasting testosterone levels below 300 ng/dL. All of them also had either preexisting cardiovascular disease or a high risk of it.[7] That population resembles the older men most likely to be offered treatment.

What TRAVERSE settled

The primary endpoint occurred in 7.0% of the testosterone group and 7.3% of the placebo group, which met the prespecified noninferiority standard.[7] Current evidence therefore does not support the claim that TRT broadly increases heart attack or stroke risk in hypogonadal men like those studied.

Earlier views on TRT cardiovascular safety were shaped by small, conflicting studies and varied prescribing patterns. With 5,246 randomized men, TRAVERSE addressed the question directly.[7]

What risks still need discussion

Noninferior for MACE does not mean risk free. TRAVERSE found a higher incidence of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group.[7] Those findings should be part of informed consent, especially for men with prior deep vein thrombosis, pulmonary embolism, arrhythmia, or kidney disease.

Sleep apnea and erythrocytosis

In a randomized trial in obese men with severe obstructive sleep apnea, testosterone worsened breathing during sleep only temporarily.[11] Testosterone therapy also raises hematocrit. The Endocrine Society guideline calls for measuring hematocrit as part of a standardized monitoring plan during treatment.[1] [9]

Obstructive sleep apnea means repeated airway collapse during sleep, causing intermittent drops in oxygen. Erythrocytosis means an abnormally high red blood cell concentration, usually tracked by hematocrit.

Sleep apnea is not an automatic reason to avoid treatment

A 2012 randomized placebo controlled trial enrolled 67 obese men with severe obstructive sleep apnea.[11] Testosterone injections worsened the oxygen desaturation index and nighttime oxygen levels at 7 weeks. By 18 weeks, the difference from placebo was no longer significant.[11] The Endocrine Society guideline lists untreated severe obstructive sleep apnea, not sleep apnea in general, among the conditions in which testosterone therapy should not be started.[1]

In clinical practice, the better approach is parallel management. Men with both hypogonadism and sleep apnea should have both conditions addressed, rather than assuming one diagnosis fully explains the other. Testosterone is not a treatment for sleep apnea. Untreated sleep apnea can itself worsen fatigue, low mood, sexual symptoms, and cardiometabolic risk.

Why hematocrit has to be monitored

According to the Endocrine Society guideline, men on testosterone therapy should have hematocrit measured under a standardized monitoring plan.[1] An elevated hematocrit is a reason not to start treatment.[1] In pooled trials, testosterone raised hematocrit by about 3 percentage points on average, a change whose clinical significance is still unknown.[9] The guideline advises stopping therapy when hematocrit exceeds 54% until it falls to a safe level.[1]

Formulation matters. TRAVERSE used a transdermal testosterone gel.[7] Erythrocytosis is more frequent with injectable testosterone than with gels. The hematocrit findings of a gel trial should therefore not be assumed to apply equally to injectable regimens.

Options for managing a high hematocrit include pausing or reducing the dose, switching formulation, or venesection when needed.[1] For the lab sequence and follow up testing strategy, see The complete low testosterone testing guide.

Genetic conditions linked to low testosterone

Genetic disorders are uncommon but important causes of low testosterone, and Klinefelter syndrome is the most prevalent of them. A Danish national registry study estimated its prevalence at 153 per 100,000 males after adjustment for maternal age, or about 1 in 650.[12]

Primary hypogonadism means the testes cannot produce enough testosterone even when the brain is sending the correct signals.

Klinefelter syndrome is common and often missed

The same registry study found that only about one fourth of adult men with Klinefelter syndrome had been diagnosed.[12] Fewer than 10% of expected cases were diagnosed before puberty. The authors noted that delayed testosterone treatment may lead to reduced muscle and bone mass and a subsequent risk of osteoporosis.[12] Klinefelter syndrome, usually 47,XXY, is associated with primary hypogonadism, infertility, and possible cognitive or psychosocial effects.

These men do not fit the same management pathway as men with acquired, potentially reversible hypogonadism. The condition is lifelong, and fertility counseling is central from the start.

Other inherited causes also change management

Other inherited causes include myotonic dystrophy, some disorders of sex development, and Kennedy disease, which involves an androgen receptor CAG repeat expansion. These conditions can alter both testosterone production and androgen action at the tissue level.

Inherited forms of hypogonadism usually require a different long term plan than acquired functional cases. For the treatment importance of this distinction, see Primary vs secondary hypogonadism: where the problem starts and why it changes everything.

Myth vs fact

Myth: TRT causes prostate cancer.

Fact: Pooled trial data do not show adverse prostate outcomes with testosterone therapy.[9] Existing prostate cancer remains a reason not to start treatment.[1]

Myth: Testosterone always worsens BPH and urination.

Fact: A meta analysis of 14 randomized trials found no significant worsening of lower urinary tract symptoms with TRT.[8] The main uncertainty is in men with severe baseline symptoms, a group in which the Endocrine Society advises against starting testosterone.[1]

Myth: Testosterone is a treatment for major depression.

Fact: Testosterone produced only a small reduction in depressive symptoms in a meta analysis of heterogeneous randomized trials.[3] Antidepressants remain the first line treatment for depressive disorders.[3]

Myth: Sleep apnea means a man cannot use testosterone.

Fact: The Endocrine Society guideline advises against starting testosterone when severe sleep apnea is untreated, not in all men with sleep apnea.[1] In one randomized trial in obese men with severe sleep apnea, testosterone worsened nighttime oxygen levels at 7 weeks but not significantly at 18 weeks, so monitoring is sensible.[11]

Myth: A high hematocrit on TRT means immediate danger.

Fact: A rise in hematocrit is a recognized adverse effect of testosterone therapy.[9] It is usually managed with dose adjustment, formulation change, or venesection. The main action point is careful monitoring, with therapy paused if hematocrit rises above 54%.[1]

Bottom line

In men with confirmed hypogonadism, low testosterone is linked to depressive symptoms, bone loss, and muscle loss, and treatment raises several specific safety questions. TRAVERSE found no increase in major cardiovascular events with testosterone gel, and pooled trial data do not show adverse prostate outcomes.[7] [9] Correct diagnosis comes first. A low testosterone result alone is not enough, and LH and FSH are needed to classify the cause before any treatment decision is made.[1] [2] For the full diagnostic and treatment roadmap, see the Low Testosterone hub.

Veedma offers testing that includes total and free testosterone measured by LC-MS/MS with LH and FSH, or a review of labs a man already has. Licensed providers prescribe enclomiphene or the enclomiphene plus tadalafil tablet when appropriate. Enclomiphene is not an FDA-approved drug; it is prescribed after a provider confirms the diagnosis and is compounded by a licensed U.S. pharmacy.

References

  1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103:1715-1744. PMID: 29562364
  2. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200:423-432. PMID: 29601923
  3. Walther A, Breidenstein J, Miller R. Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2019;76:31-40. PMID: 30427999
  4. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374:611-24. PMID: 26886521
  5. Rochira V. Late-onset Hypogonadism: Bone health. Andrology. 2020;8:1539-1550. PMID: 32469467
  6. Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, et al. Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial. JAMA Intern Med. 2017;177:471-479. PMID: 28241231
  7. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389:107-117. PMID: 37326322
  8. Kohn TP, Mata DA, Ramasamy R, et al. Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis. Eur Urol. 2016;69:1083-90. PMID: 26874809
  9. Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95:2560-75. PMID: 20525906
  10. Isidori AM, Giannetta E, Pozza C, et al. Androgens, cardiovascular disease and osteoporosis. J Endocrinol Invest. 2005;28:73-9. PMID: 16550728
  11. Hoyos CM, Killick R, Yee BJ, et al. Effects of testosterone therapy on sleep and breathing in obese men with severe obstructive sleep apnoea: a randomized placebo-controlled trial. Clin Endocrinol (Oxf). 2012;77:599-607. PMID: 22512435
  12. Bojesen A, Juul S, Gravholt CH. Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. J Clin Endocrinol Metab. 2003;88:622-6. PMID: 12574191

Start with a lab panel

Get a clinical review of your results and health history, with an explanation of the decision and next steps in your patient chat. If you are eligible and want treatment, choose a plan and save a card to book a video visit at no extra visit fee. Treatment billing starts only if prescribed.

Order your lab panel

Prefer short video breakdowns? Follow @veedma.men on TikTok for quick, study-backed men's hormone explainers.

Vladimir Kotlov, MD

Vladimir Kotlov, MD: Founder & CEO at Veedma

Vladimir Kotlov, MD is the founder of Veedma. A urologist by training, he led a urology department at a fertility and reproductive clinic where he managed a team of 30+ clinicians and improved IVF outcomes by 24%. He then moved to Silicon Valley and spent five years advising healthtech companies before founding Veedma to help men access evidence-based hormone optimization and fertility care.